Pharmac is proposing to widen access to a medicine used in the treatment of chronic heart failure.
The medicine, empagliflozin, would be available to people who have chronic heart failure with reduced ejection fraction – about half of all people with chronic heart failure.
Pharmac director of pharmaceuticals Geraldine MacGibbon says empagliflozin is a medicine that can give people more time with their loved ones and lessens the time spent in hospital.
Inequities in health between Māori, the indigenous people of Aotearoa New Zealand, and non-Māori have been evident throughout the colonial history of the country. Read more
The New Zealand (NZ) Pae Ora (Healthy Futures) health reforms came into effect in July 2022 with the establishment of Health New Zealand (HNZ) (Te Whatu Ora) and the Māori Health Authority (MHA) (Te Aka Whai Ora) – the organisations charged for healthcare provision...
The Government has made much of the need to keep frontline services fully functioning, even when costs might be trimmed in the so-called “back office”. Read...
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI